Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02GEC
|
||||
Former ID |
DAP000387
|
||||
Drug Name |
Omalizumab
|
||||
Synonyms |
Xolair; Omalizumab (genetical recombination); Xolair (TN); Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN)
|
||||
Drug Type |
Monoclonal antibody
|
||||
Indication | Asthma; Chronic idiopathic urticaria [ICD10:J45, L50] | Approved | [1], [2], [3], [4] | ||
Chronic idiopathic urticaria [ICD9: 708; ICD10:L50] | Phase 2 | [1], [2] | |||
Therapeutic Class |
Antiasthmatic Agents
|
||||
Company |
National University Hospital, Singapore|National University, Singapore
|
||||
Formula |
C6450H9916N1714O2023S38
|
||||
CAS Number |
CAS 242138-07-4
|
||||
PubChem Substance ID | |||||
SuperDrug ATC ID |
R03DX05
|
||||
Target and Pathway | |||||
Target(s) | High affinity immunoglobulin epsilon receptor | Target Info | Modulator | [5] | |
KEGG Pathway | Sphingolipid signaling pathway | ||||
Fc epsilon RI signaling pathway | |||||
Asthma | |||||
PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
Reactome | Fc epsilon receptor (FCERI) signaling | ||||
Role of LAT2/NTAL/LAB on calcium mobilization | |||||
FCERI mediated MAPK activation | |||||
FCERI mediated Ca+2 mobilization | |||||
FCERI mediated NF-kB activation | |||||
WikiPathways | IL1 and megakaryotyces in obesity | ||||
Fc epsilon receptor (FCERI) signaling | |||||
References | |||||
REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6890). | ||||
REF 3 | ClinicalTrials.gov (NCT00546143) Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma | ||||
REF 4 | ClinicalTrials.gov (NCT01701583) Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria | ||||
REF 5 | The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. doi: 10.1038/nrd3792. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.